Pulmonary Vein Isolation in Patients with Atrial Fibrillation: What Did We Learn from the SHAM Ablation Studies?
Abstract Purpose of Review This review summarizes the findings and key lessons from sham-controlled trials of pulmonary vein isolation (PVI) in atrial fibrillation (AF). Recent Findings SHAM-PVI, PFA-SHAM, and PVI-SHAM-AF demonstrated lower AF recurrence and burden after PVI compared with sham. Quality of life improved after PVI in all trials, but PVI-SHAM-AF did not show superiority over sham because of similar improvements with sham, reflecting the contribution of nonspecific treatment effects such as expectancy, clinical attention and the Hawthorne effect. The trials demonstrate that invasive sham-controlled studies are feasible, safe, and can achieve blinding. Summary Reductions in AF recurrence and burden with PVI do not consistently translate into greater improvements in quality of life than sham. The contribution of nonspecific treatment effects may have been underestimated in previous trials. Further studies should characterize the relationship between AF burden and symptoms and identify patients most likely to derive symptomatic benefit from PVI.
Authors
- Tobias Uhe (ORCID: https://orcid.org/0000-0003-2543-2427)
- Samira Beimel
- Patrick Haag (née Dilk)
- Rolf Wachter
- Nikolaos Dagres
Institutions
- Deutsches Herzzentrum der Charité (DE)
- Leipzig Heart Institute (DE)
- University Hospital Leipzig (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Current Cardiology Reports
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1007/s11886-026-02450-9
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00